These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Eosinophilia-myalgia syndrome]. Heuschling C Bull Soc Sci Med Grand Duche Luxemb; 1992; 129(2):17-23. PubMed ID: 1340406 [No Abstract] [Full Text] [Related]
27. [A lesson on the purity of pharmaceutical products derived from biotechnology: eosinophilia-myalgia syndrome]. Boll Chim Farm; 1995; 134(7):394-5. PubMed ID: 7546544 [No Abstract] [Full Text] [Related]
28. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395 [No Abstract] [Full Text] [Related]
29. Fibromyalgia, psychiatric disorders, and assessment of the longterm outcome of eosinophilia-myalgia syndrome. Hudson JI; Pope HG; Carter WP; Daniels SR J Rheumatol Suppl; 1996 Oct; 46():37-42; discussion 42-3. PubMed ID: 8895180 [TBL] [Abstract][Full Text] [Related]
30. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases. Sullivan EA; Staehling N; Philen RM J Rheumatol; 1996 Oct; 23(10):1784-7. PubMed ID: 8895159 [TBL] [Abstract][Full Text] [Related]
31. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique. Shapiro S J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic bias in clinical decision making: an example of L-tryptophan and the diagnosis of eosinophilia-myalgia syndrome. Wagner KR; Elmore JG; Horwitz RI J Rheumatol; 1996 Dec; 23(12):2079-85. PubMed ID: 8970044 [TBL] [Abstract][Full Text] [Related]
34. Abnormalities of the coronary arteries, neural structures and conduction system of the heart observed postmortem in the eosinophilia-myalgia syndrome, with a discussion of comparative findings from the toxic oil syndrome. James TN Trans Am Clin Climatol Assoc; 1991; 102():52-81; discussion 81-3. PubMed ID: 2130570 [No Abstract] [Full Text] [Related]
35. Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements. Clauw DJ; Flockhart DA; Mullins W; Katz P; Medsger TA J Rheumatol; 1994 Dec; 21(12):2385-7. PubMed ID: 7699648 [TBL] [Abstract][Full Text] [Related]
36. Elevated L-kynurenine level and its normalization by prednisolone in a patient with eosinophilia-myalgia syndrome. Hisatomi A; Kubota A; Ohashi M; Umeda F; Nawata H; Imamura T; Nagata T Fukuoka Igaku Zasshi; 1997 Jan; 88(1):11-7. PubMed ID: 9037890 [TBL] [Abstract][Full Text] [Related]
37. The eosinophilia-myalgia syndrome--guidelines for patient care. Hertzman PA; Kaufman LD; Love LA; Mease PJ; Philen RM; Pincus T; Rosenberg NL; Silver R; Varga J; Clauw DJ J Rheumatol; 1995 Jan; 22(1):161-3. PubMed ID: 7699664 [No Abstract] [Full Text] [Related]
38. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome. Kilbourne EM; Philen RM; Kamb ML; Falk H J Rheumatol Suppl; 1996 Oct; 46():81-8; discussion 89-91. PubMed ID: 8895184 [TBL] [Abstract][Full Text] [Related]
39. The evolving spectrum of eosinophilia myalgia syndrome. Kaufman LD Rheum Dis Clin North Am; 1994 Nov; 20(4):973-94. PubMed ID: 7855332 [TBL] [Abstract][Full Text] [Related]